Vous avez cherché: botox (Lituanien - Anglais)

botox (n = 155)
botox (n=155)

8, 2 proc. – botox).
8.2% in the cervical dystonia phase iii study, respectively).

vienintel kart sunki disfagija pasireisk botox grupje.
one case with severe dysphagia was reported in the botox group.

vienintelį kartą sunki disfagija pasireiškė botox grupėje.
the only severe case of dysphagia occurred in the botox group.

botox grupje.visi snr buvo vertinti kaip nesusij su gydymu.
all of the saes were assessed as unrelated to treatment.

susijusi nepageidaujam reiskini atveju (xeomin versus botox)
proportions (xeomin versus botox)

vis dlto nra pozymi, kad xeomin bt stipresnis antigenas uz botox.
however, there is no indication of a higher antigenic potential of xeomin compared to botox.

1, 8 proc. ­ botox; iii fazs blefarospazm tyrimo atveju:
1.8% for botox in the pooled sample and 6.1% for xeomin vs.

reikt pazymti, kad vienintel kart sunki disfagija pasireisk botox grupje.
of note, the only severe case of dysphagia occurred in a botox treated patient.

reikėtų pažymėti, kad vienintelį kartą sunki disfagija pasireiškė botox grupėje.
of note, the only severe case of dysphagia occurred in a botox treated patient.

taigi xeomin grupje pasireisk daugiau su gydymu susijusi nepageidaujam reiskini negu botox grupje.
thus, related adverse effects occurred more frequently in the xeomin group compared to botox.

neklinikiniame tyrime xeomin imunogeniskas nesiskyr nuo botox imunogenisko, net kai dozs aiskiai virsijo zmonms rekomenduojam doz.
in the non-clinical study, xeomin was not more or less immunogenic than botox even at dose levels clearly exceeding the recommended human dose.

botox grupje 45 is 152 pacient (29. 6 proc.) pranes apie 62 nepageidaujamus reiskinius.
for botox, 45 out of 152 patients (29.6%) reported a total of 62 adverse events.

atsizvelgiant siuos faktus, mazai tiktina, jog antrinio gydymo xeomin injekcijomis neveiksmingumo daznumas bt didesnis uz botox.
by reason of these facts it is implausible, that injection of xeomin would lead to more frequent secondary therapeutic failures than botox.

6, 1 proc. ­ xeomin vs.4, 6 proc. ­ botox) .ptoz pasireisk tik bps pacientams.
4.6% for botox in the blepharospasm phase iii study) and occurred in bps patients only.

siuose saugumo duomenims gauti skirtuose tyrimuose is viso dalyvavo 908 pacientai, is kuri 466 asmenys buvo gydyti xeomin, o 442 ­ botox.
overall, safety data from 908 participants have been included in these trials, 466 subjects were treated with xeomin and 442 subjects were treated with botox.

sis tyrimas parod, kad xeomin (70­300 v) nra maziau veiksmingas uz botox (70­300 v) .
this study showed the non-inferiority of xeomin (70-300 u) compared to botox (70-300 u) .

dazniausiai pasireiskiantis nepageidaujamas reiskinys buvo ptoz (xeomin ­ 6, 1 proc.; botox ­ 4, 6 proc.) .
the most frequently reported adverse event was ptosis (xeomin 6.1%; botox 4.6%) .

iii fazs tyrim, susijusi su imunogeniskumo vertinimu, duomen vert ribota, kadangi pacientams buvo skirtas isankstinis gydymas botox, o xeomin buvo skirtas tik vien kart.
the informational value of the phase iii studies concerning immunogenicity is limited, as the patients were pretreated with botox, and xeomin was administered only once.

ii fazs spazmins kreivakaklysts tyrimo metu pranesta apie vien su gydymu (botox) nesusijus mirties atvej (colon carcinoma) .
one death (colon carcinoma) , assessed as unrelated to study treatment (botox) , was reported during the phase ii cervical dystonia study.